vs
Side-by-side financial comparison of Axsome Therapeutics, Inc. (AXSM) and Origin Bancorp, Inc. (OBK). Click either name above to swap in a different company.
Axsome Therapeutics, Inc. is the larger business by last-quarter revenue ($196.0M vs $104.0M, roughly 1.9× Origin Bancorp, Inc.). Origin Bancorp, Inc. runs the higher net margin — 26.6% vs -14.6%, a 41.2% gap on every dollar of revenue. Over the past eight quarters, Axsome Therapeutics, Inc.'s revenue compounded faster (61.7% CAGR vs 3.9%).
Jazz Pharmaceuticals plc is a global biopharmaceutical company with a focus on oncology and neuroscience. It was founded in 2003 in California, United States and is now headquartered in Dublin, Ireland.
Southern Bancorp is a community development financial institution headquartered in Arkadelphia, Arkansas. It was founded in 1986 as Southern Development Bancorporation, and is often referred to simply as "Southern".
AXSM vs OBK — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $196.0M | $104.0M |
| Net Profit | $-28.6M | $27.7M |
| Gross Margin | — | — |
| Operating Margin | -13.8% | — |
| Net Margin | -14.6% | 26.6% |
| Revenue YoY | 65.0% | — |
| Net Profit YoY | 61.9% | — |
| EPS (diluted) | $-0.55 | $0.89 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $104.0M | ||
| Q4 25 | $196.0M | $103.4M | ||
| Q3 25 | $171.0M | $109.8M | ||
| Q2 25 | $150.0M | $83.5M | ||
| Q1 25 | $121.5M | $94.1M | ||
| Q4 24 | $118.8M | $78.3M | ||
| Q3 24 | $104.8M | $90.8M | ||
| Q2 24 | $87.2M | $96.4M |
| Q1 26 | — | $27.7M | ||
| Q4 25 | $-28.6M | $29.5M | ||
| Q3 25 | $-47.2M | $8.6M | ||
| Q2 25 | $-48.0M | $14.6M | ||
| Q1 25 | $-59.4M | $22.4M | ||
| Q4 24 | $-74.9M | $14.3M | ||
| Q3 24 | $-64.6M | $18.6M | ||
| Q2 24 | $-79.3M | $21.0M |
| Q1 26 | — | — | ||
| Q4 25 | -13.8% | 36.2% | ||
| Q3 25 | -27.0% | 10.0% | ||
| Q2 25 | -24.5% | 22.3% | ||
| Q1 25 | -46.9% | 30.4% | ||
| Q4 24 | -61.1% | 23.0% | ||
| Q3 24 | -59.8% | 26.1% | ||
| Q2 24 | -89.5% | 27.7% |
| Q1 26 | — | 26.6% | ||
| Q4 25 | -14.6% | 28.5% | ||
| Q3 25 | -27.6% | 7.9% | ||
| Q2 25 | -32.0% | 17.5% | ||
| Q1 25 | -48.9% | 23.8% | ||
| Q4 24 | -63.1% | 18.2% | ||
| Q3 24 | -61.7% | 20.5% | ||
| Q2 24 | -91.0% | 21.8% |
| Q1 26 | — | $0.89 | ||
| Q4 25 | $-0.55 | $0.95 | ||
| Q3 25 | $-0.94 | $0.27 | ||
| Q2 25 | $-0.97 | $0.47 | ||
| Q1 25 | $-1.22 | $0.71 | ||
| Q4 24 | $-1.54 | $0.45 | ||
| Q3 24 | $-1.34 | $0.60 | ||
| Q2 24 | $-1.67 | $0.67 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $322.9M | — |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $88.3M | $1.3B |
| Total Assets | $689.8M | $10.2B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $322.9M | $424.2M | ||
| Q3 25 | $325.3M | $626.9M | ||
| Q2 25 | $303.0M | $334.1M | ||
| Q1 25 | $300.9M | $486.2M | ||
| Q4 24 | $315.4M | $470.2M | ||
| Q3 24 | $327.3M | $321.2M | ||
| Q2 24 | $315.7M | $288.1M |
| Q1 26 | — | $1.3B | ||
| Q4 25 | $88.3M | $1.2B | ||
| Q3 25 | $73.7M | $1.2B | ||
| Q2 25 | $73.1M | $1.2B | ||
| Q1 25 | $53.2M | $1.2B | ||
| Q4 24 | $57.0M | $1.1B | ||
| Q3 24 | $92.9M | $1.1B | ||
| Q2 24 | $102.9M | $1.1B |
| Q1 26 | — | $10.2B | ||
| Q4 25 | $689.8M | $9.7B | ||
| Q3 25 | $669.3M | $9.8B | ||
| Q2 25 | $639.8M | $9.7B | ||
| Q1 25 | $596.7M | $9.8B | ||
| Q4 24 | $568.5M | $9.7B | ||
| Q3 24 | $561.5M | $10.0B | ||
| Q2 24 | $548.2M | $9.9B |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-18.7M | — |
| Free Cash FlowOCF − Capex | $-18.7M | — |
| FCF MarginFCF / Revenue | -9.6% | — |
| Capex IntensityCapex / Revenue | 0.0% | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $-93.9M | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $-18.7M | $158.9M | ||
| Q3 25 | $1.0M | $59.3M | ||
| Q2 25 | $-32.4M | $20.6M | ||
| Q1 25 | $-43.4M | $35.6M | ||
| Q4 24 | $-26.2M | $108.5M | ||
| Q3 24 | $-18.6M | $39.6M | ||
| Q2 24 | $-30.1M | $11.9M |
| Q1 26 | — | — | ||
| Q4 25 | $-18.7M | $151.1M | ||
| Q3 25 | $988.0K | $56.8M | ||
| Q2 25 | $-32.4M | $19.6M | ||
| Q1 25 | $-43.7M | $34.8M | ||
| Q4 24 | $-26.2M | $86.4M | ||
| Q3 24 | $-18.7M | $32.2M | ||
| Q2 24 | $-30.2M | $6.5M |
| Q1 26 | — | — | ||
| Q4 25 | -9.6% | 146.0% | ||
| Q3 25 | 0.6% | 51.7% | ||
| Q2 25 | -21.6% | 23.5% | ||
| Q1 25 | -36.0% | 37.0% | ||
| Q4 24 | -22.1% | 110.3% | ||
| Q3 24 | -17.9% | 35.5% | ||
| Q2 24 | -34.6% | 6.8% |
| Q1 26 | — | — | ||
| Q4 25 | 0.0% | 7.6% | ||
| Q3 25 | 0.0% | 2.3% | ||
| Q2 25 | 0.0% | 1.2% | ||
| Q1 25 | 0.3% | 0.8% | ||
| Q4 24 | 0.0% | 28.1% | ||
| Q3 24 | 0.1% | 8.1% | ||
| Q2 24 | 0.1% | 5.6% |
| Q1 26 | — | — | ||
| Q4 25 | — | 5.38× | ||
| Q3 25 | — | 6.88× | ||
| Q2 25 | — | 1.41× | ||
| Q1 25 | — | 1.59× | ||
| Q4 24 | — | 7.60× | ||
| Q3 24 | — | 2.13× | ||
| Q2 24 | — | 0.57× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
AXSM
Segment breakdown not available.
OBK
| Net Interest Income | $87.2M | 84% |
| Noninterest Income | $16.8M | 16% |
